01—Abstract
Summary
Summary of the 8-K filed March 16, 2026. Cited figures are marked; the original filing is the authoritative source.
DuPont de Nemours, Inc., a Delaware corporation, filed this Current Report under Item 7.01 (Regulation FD Disclosure) on March 16, 2026 to state that it expects to close the previously announced sale of its aramids business (Kevlar® and Nomex®) to Arclin on April 1, 2026.
The filing states that all regulatory conditions to close the sale were satisfied as of March 10, 2026. Arclin is identified in the filing as ARC Falcon Holdings, L.P. and New Arclin U.S. Holding Corp., a wholly-owned subsidiary of Holdings. The filing is informational and furnished rather than filed for Section 18 purposes.
It does not provide financial results, purchase price, or other financial figures. The forward-looking statements caution that closing remains subject to the parties' ability to meet the timing and other conditions of the transaction, and it notes DuPont's ownership of a minority interest in the future Arclin company, whose effect on DuPont's results of operations is a stated risk factor.
For investors, the key takeaway is that the aramids divestiture is expected to close on April 1, 2026, with regulatory approvals already obtained. The filing does not describe the transaction's financial terms or expected proceeds.
02—Key points
Key Highlights
- DuPont expects to close the sale of its aramids business (Kevlar® and Nomex®) to Arclin on April 1, 2026.
- All regulatory conditions to close the sale transaction were satisfied as of March 10, 2026.
- The buyer is identified as ARC Falcon Holdings, L.P. and New Arclin U.S. Holding Corp., a wholly-owned subsidiary of Holdings.
- DuPont will hold a minority interest in the future Arclin company, according to the forward-looking statements section.
- The information is furnished under Item 7.01 (Regulation FD Disclosure) and is not deemed filed for Section 18 of the Exchange Act.
- The filing does not disclose the purchase price, proceeds, or financial impact of the transaction.
03—Questions
Frequently Asked Questions
What is being sold, and to whom?
DuPont is selling its aramids business, which includes Kevlar® and Nomex®, to Arclin. The filing identifies the buyer entities as ARC Falcon Holdings, L.P. and New Arclin U.S. Holding Corp., a wholly-owned subsidiary of Holdings.
When is the transaction expected to close?
DuPont expects the sale to close on April 1, 2026, as stated in the filing dated March 16, 2026.
Have the regulatory approvals been obtained?
Yes. The filing states that all regulatory conditions to close the sale transaction were satisfied as of March 10, 2026.
Will DuPont retain any interest in the business after the sale?
Yes. The forward-looking statements section refers to DuPont's ownership of a minority interest in the future Arclin company, and notes that this ownership could affect DuPont's results of operations.
What risks could still affect the closing?
The filing cautions that closing depends on the parties' ability to meet expectations on timing, completion, and tax treatment, and on satisfying the other conditions of the transaction. It also lists separation-related risks and the risk of impairment.
04—Continue